These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3458444)

  • 21. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia.
    Browman G; Goldberg J; Gottlieb AJ; Preisler HD; Azarnia N; Priore RL; Brennan JK; Vogler WR; Winton EF; Miller KB
    Am J Hematol; 1983 Nov; 15(3):227-35. PubMed ID: 6638009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
    Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
    N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
    Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
    Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
    Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J
    Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
    Rubnitz JE; Razzouk BI; Srivastava DK; Pui CH; Ribeiro RC; Santana VM
    Leuk Res; 2004 Apr; 28(4):349-52. PubMed ID: 15109533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of acute myeloid leukemia in children.
    Nesbit ME; Woods WG
    Leukemia; 1992; 6 Suppl 2():31-5. PubMed ID: 1578938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
    Rees JK; Gray RG; Wheatley K
    Br J Haematol; 1996 Jul; 94(1):89-98. PubMed ID: 8757514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
    Gore SD; Burke PJ; Weng LJ
    Leuk Lymphoma; 1998 Apr; 29(3-4):339-50. PubMed ID: 9684931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.